Henry is associate director of product management, responsible for the Gibco and Invitrogen-branded protein expression portfolio at Thermo Fisher Scientific. He has directed or guided development of such products as Lipofectamine® LTX, Lipofectamine® RNAiMAX, Lipofectamine® 3000, the FreeStyle™ MAX CHO Expression System, the Expi293™ Expression System and the ExpiCHO Expression System. Henry previously worked for small biotech companies in gene delivery and gene therapy. He received his Ph.D. from Harvard University and did his post-doctoral training at the University of Pennsylvania.

Rich Altman has 29 years of experience working in the pharmaceutical industry. In 2016, he joined the Protein Technologies Mammalian Expression group at Amgen San Francisco, supporting biologics drug development. Prior to Amgen, he worked for several pharmaceutical companies on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

Jonathan Zmuda is a Director of Cell Biology at Thermo Fisher Scientific in Frederick, Maryland. Jon leads a team dedicated to discovering and developing new technologies and products useful for cell biology applications, including transient protein expression, advanced cell culture, and rare-cell analysis. He received his Ph.D. in Cell Biology from the University of Maryland, College Park.

In 2016 Konrad joined the Protein and Cell Sciences group at EMD Serono in Billerica, MA as a member of the research stage protein expression team. Prior to EMD Serono Konrad worked for 25 years as a research scientist at Biogen in Cambridge, MA where he developed and managed a protein expression and purification core team. His expertise includes transient protein expression in mammalian and insect cells, both at small and large scale, using shake flasks, stir-tank bioreactors, and rocking bioreactor systems. Konrad's focus is optimization of protein quality and yield by designing growth conditions and feed strategies. He also brings significant experience with developing, selecting and culturing hybridoma and stable mammalian cell lines.